Uncategorized

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

Published

on

Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version